ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Rating) was down 1.2% during mid-day trading on Thursday . The company traded as low as $6.33 and last traded at $6.40. Approximately 145,504 shares traded hands during trading, a decline of 37% from the average daily volume of 231,594 shares. The stock had previously closed at $6.48.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SPRY. SVB Leerink initiated coverage on ARS Pharmaceuticals in a report on Tuesday, December 13th. They issued an "outperform" rating and a $14.00 price target for the company. William Blair began coverage on ARS Pharmaceuticals in a research note on Tuesday, January 3rd. They issued an "outperform" rating and a $17.00 target price for the company.

ARS Pharmaceuticals Price Performance

The stock's fifty day moving average is $7.29. The company has a market cap of $230.77 million, a PE ratio of -2.64 and a beta of 0.20.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, CFO Kathleen D. Scott acquired 8,250 shares of the business's stock in a transaction dated Tuesday, November 29th. The shares were bought at an average cost of $6.24 per share, for a total transaction of $51,480.00. Following the acquisition, the chief financial officer now directly owns 8,250 shares in the company, valued at approximately $51,480. The purchase was disclosed in a filing with the SEC, which is available through this link. 34.40% of the stock is owned by company insiders.

ARS Pharmaceuticals Company Profile

(Get Rating)

ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Featured Articles

• Get a free copy of the StockNews.com research report on ARS Pharmaceuticals (SPRY)
• The Future Of E-Commerce: Analysis And New Data
• Chevron Delights Shareholders with $75 Billion in Share Buybacks
• Levi Strauss Is A Good Fit For Income Investors
• 3 Small Caps That Have Big Upside
• Mullen Automotive: The Good News, The Bad And The Ugly Outlook

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.